Seizure News and Research

Latest Seizure News and Research

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Researchers discover new compound to fight against shingles

Researchers at the University of Georgia and Yale University have discovered a compound with the potential to be more effective than existing agents in treating the very painful blisters known as shingles-a condition that affects up to 30 percent of Americans, mostly elderly, and for which no specific treatment exists.

22 Apr 2011

FDA warns four firms to stop making unproven MRSA prevention claims

The U.S. Food and Drug Administration issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria (MRSA).

21 Apr 2011

Neurelis completes dosing in intranasal diazepam formulation study

Neurelis, Inc. today announced the completion of subject dosing in a randomized crossover study assessing diazepam pharmacokinetics and bioavailability after administration of two proprietary formulations of intranasal diazepam and intravenous injection.

21 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

New study finds treatment-resistant epilepsy common in idiopathic autism

A new study found that treatment-resistant epilepsy (TRE) is common in idiopathic autism. Early age at the onset of seizures and delayed global development were associated with a higher frequency of resistance to antiepileptic drugs (AEDs). Full findings appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy (ILAE).

19 Apr 2011

Topamax recall by Johnson & Johnson

Johnson & Johnson this Thursday has announced a recall of 57,000 bottles of the prescription anti-seizure medication Topamax following consumer complaints of an “uncharacteristic odor.”

15 Apr 2011

Perampanel drug can effectively treat seizures in patients with epilepsy

A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug.

15 Apr 2011

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.

12 Apr 2011

New weight loss pill - combination of two existing drugs

According to the latest research on obesity treatments there is now a new weapon in the battle for weight loss. It combines two existing drugs that have resulted in twice as much weight loss as the only approved long-term anti-obesity medication.

10 Apr 2011

Pitt, UPCI researchers' cancer studies presented at AACR meeting

How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.

7 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

U.S. Marshals, FDA seize $6 million worth Triad antiseptic products

U.S. Marshals, at the request of the U.S. Food and Drug Administration, today seized more than $6 million in products distributed by Triad Group Inc., at the company's facility in Hartland, Wis.

7 Apr 2011

New stereo-EEG method can detect epileptic foci during surgeries

The neurosurgery department of HUCH has started to utilize stereo-EEG method for localizing the epileptic focus in severe epilepsy for epilepsy surgery purposes. The department is also getting ready to introduce the so-called deep brain stimulation therapy in the treatment of epilepsy.

30 Mar 2011

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Commission has granted marketing authorisation for Trobalt as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

30 Mar 2011

CryoLife to acquire Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, and Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of patients with refractory angina resulting from diffuse coronary artery disease, today announced that the boards of directors of both companies have approved a definitive agreement under which CryoLife will acquire all of the outstanding shares of Cardiogenesis for $0.457 per share.

29 Mar 2011

Findings conflict with traditional view of how epileptic seizures begin

The first study to examine the activity of hundreds of individual human brain cells during seizures has found that seizures begin with extremely diverse neuronal activity, contrary to the classic view that they are characterized by massively synchronized activity.

28 Mar 2011

Mosquitoes carry risk of Murray Valley encephalitis warn Victorian health authorities

After detecting some new cases of Murray Valley encephalitis in chickens, health authorities have warned Victorians to protect themselves from mosquito bites. Victoria's chief health officer, Dr John Carnie warned that the deadly disease had been detected in "sentinel" chickens at Cobram, Rutherglen, Toolamba and Bendigo. “These latest detections follow positive results in chickens in similar areas a month ago, including Barmah and Kerang… Evidence of the virus is again present in these areas,” Dr Carnie said.

24 Mar 2011

Cardiac pacing may help epilepsy patients with seizure-related falls

Mayo Clinic researchers have found that cardiac pacing may help epilepsy patients with seizure-related falls due to ictal asystole, an unusual condition in which the heart stops beating during an epileptic seizure. The study was recently published in the journal Epilepsia.

24 Mar 2011